Genes, Cells, and MiRNAs

Edit Gara, Mitja Lainscak

Abstract


Novel methods to treat HF include gene, cell and microRNA  delivery. There have been few gene therapy trials in HF. The CUPID I and II trials with AAV1.SERCA2a showed unconvincing results. The STOP-HF trial using direct intra-myocardial injection of a non-integrating plasmid vector carrying stromal cell-derived factor-1 showed no clinical effects and the AC6 gene transfer trial used IC infusion of escalating doses of Ad5.hAC6 was similarly negative. Despite high hopes stem cell trials to date in HF have not shown convincing clinical benefits. More recent clinical trials in this area have investigated the injection of cell stimulating paracrine factors (peptides, small molecules, hormone-like molecules) without actual cell delivery. Micro-RNA’s (miRNAs) are small non-coding RNA strands, comprising 19-25 nucleotides, that have a distinct signalling role and a various patterns of expression in ischaemic myocardium, hypertrophy, cardiomyopathies, and overt HF. They act at the post-transcriptional regulation level. Numerous novel miRNAs have been discovered, and their in-depth role has been characterised. miRNAs can serve as therapeutic substances or therapeutic targets in a range of cardiovascular diseases.   Clinical trials are likely in the near future.


Keywords


Heart Failure; Genes; Cells; MiRNAs

Full Text:

Gara-617

References


Hnatiuk AP, Ong S, Olea FD, et al. Allogeneic Mesenchymal Stromal Cells Overexpressing Mutant Human Hypoxia‐Inducible Factor 1‐α (HIF1‐α) in an Ovine Model of Acute Myocardial Infarction. J Am Heart Assoc 2016;5:e003714.

Penny WF, Hammond HK. Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction. Hum Gene Ther. 2017 May;28(5):378-384. doi: 10.1089/ hum.2016.166.

Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ, Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011 Jul 19; 124(3):304-13.

Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, Barnard D, Bouchard A, Jaski B, Lyon AR, Pogoda JM, Rudy JJ, Zsebo KM. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet. 2016 Mar 19; 387(10024):1178-86.

Chung ES, Miller L, Patel AN, Anderson RD, Mendelsohn FO, Traverse J, Silver KH, Shin J, Ewald G, Farr MJ, Anwaruddin S, Plat F, Fisher SJ, AuWerter AT, Pastore JM, Aras R, Penn MS. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial. Eur Heart J. 2015 Sep 1; 36(33):2228-38.

Hammond HK, Penny WF, Traverse JH, et al. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial. JAMA Cardiol. 2016 May 1; 1(2):163-71.

Zhang Y, Li W, Ou L, et al. Targeted delivery of human VEGF gene via complexes of magnetic nanoparticle-adenoviral vectors enhanced cardiac regeneration. PLoS One. 2012;7(7):e39490. doi: 10.1371/journal.pone.0039490.

Fernández-Avilés F, Sanz-Ruiz R, Climent AM, et al. Global position paper on cardiovascular regenerative medicine. Eur Heart J 2017;38:2532–2546.

Beer L, Mildner M, Gyongyosi M, et al. Peripheral blood mononuclear cell secretome for tissue repair. Apoptosis. 2016 Dec;21(12):1336-1353. DOI: 10.1007/s10495-016-1292-8

Menasché P, Vanneaux V, Hagège A, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: First clinical case report. Eur Heart J 2015 Volume 36, Issue 30, 7 August 2015, Pages 2011–2017, https://doi.org/10.1093/ eurheartj/ehv189

Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease [published online ahead of print August 27, 2017].N Engl J Med. 2017. doi: 10.1056/NEJMoa1707914.

Viereck J, Thum T. Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury. Circ Res. 2017 Jan 20;120(2):381-399. doi: 10.1161/ CIRCRESAHA.116.308434.

Jacobs L, Thijs L, Jin Y, et al. Heart ‘omics’ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. J Biomed Res. 2014 Sep;28(5):349-59. doi: 10.7555/JBR.28.20140045.

Romaine SPR, Tomaszewski M, Condorelli G, et al. MicroRNAs in cardiovascular disease: An introduction for clinicians. Heart 2015. Heart. 2015 Jun;101(12):921-8. doi: 10.1136/heartjnl-2013-305402.

Shewan LG, Coats AJS, Henein MY. Authors’ Responsibilities and Ethical Publishing. International Cardiovascular Forum Journal 2018;13:3-4, DOI: 10.17987/icfj.v13i0.525




DOI: https://doi.org/10.17987/icfj.v18i0.617

Copyright (c) 2019 The author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.